Arcturus Reports Results From Early-Stage Testing of Its Coronavirus Vaccine

1 min read

In an investor update on Monday, Arcturus Therapeutics Holdings (NASDAQ: ARCT) reported early-stage clinical trial results for its coronavirus vaccine candidate. The company also said that the Singapore Health Sciences Authority had granted approval to begin a phase 2 study of that candidate, ARCT-021.

Although the results indicate that the one-dose vaccine is effective at blocking the coronavirus, it produces fewer neutralizing antibodies than the vaccine made by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), and the vaccine of Moderna (NASDAQ: MRNA). Compounding that, Pfizer/BioNTech’s BNT-162b2 and Moderna’s mRNA-1273 have been approved by U.S. and European Union healthcare regulators for emergency use.

Like BNT-162b2 and mRNA-1273, Arcturus’ vaccine candidate utilizes messenger RNA to instruct the body’s cells how to combat the coronavirus.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Here’s Why Lemonade Stock Is Soaring Tuesday

Next Story

Noted Activist Investor Calls on Intel to Explore Strategic Alternatives

Latest from Blog